Zobrazeno 1 - 6
of 6
pro vyhledávání: '"David Marchisin"'
Autor:
Shan Jing, Yang Lin, Randy Dockens, David Marchisin, Bing He, Ihab G. Girgis, Anjaneya Chimalakonda, Bindu Murthy, Urvi Aras
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 12, Pp 3153-3164 (2023)
Abstract Introduction Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and
Externí odkaz:
https://doaj.org/article/138681b5e9fe48568e696414c32c2790
Autor:
Samira J. Merali, Wonkyung Byon, Yogesh T. Patel, Amira Elsrougy, David Marchisin, Vidya Perera, Weidong Chen, Bing He, Bindu Murthy
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 4, Pp 500-512 (2023)
Abstract Apixaban is an oral small‐molecule, direct factor Xa (FXa) inhibitor approved in adults for treatment of deep vein thrombosis and pulmonary embolism, and for reducing risk of venous thromboembolism recurrence after initial anticoagulant th
Externí odkaz:
https://doaj.org/article/9b743f85d5894a23873a53859c560c40
Autor:
Anjaneya, Chimalakonda, Shalabh, Singhal, Raymond, Darbenzio, Randy, Dockens, David, Marchisin, Subhashis, Banerjee, Ihab G, Girgis, John, Throup, Bing, He, Urvi, Aras, Bindu, Murthy
Publikováno v:
Clinical Pharmacology in Drug Development. 11:442-453
Deucravacitinib is a novel, oral, selective inhibitor of the intracellular signaling kinase tyrosine kinase 2. This phase 1, randomized, partially double-blind, 4-period crossover study in healthy adults was conducted to determine whether deucravacit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07ba45e3d729d1150d54b369b8bfcb9b
https://doi.org/10.1002/cpdd.1056
https://doi.org/10.1002/cpdd.1056
Autor:
Samira M Garonzik, Wonkyung Byon, Yogesh Patel, Amira Elsrougy, David Marchisin, Vidya Perera, Weidong Chen, Bing He, Bindu Murthy
Publikováno v:
Circulation. 144
Introduction: Standard-of-care antithrombotics in pediatric subjects (peds) include unfractionated/LMW heparin, aspirin, and vitamin K antagonists. Apixaban, a direct factor Xa (FXa) inhibitor indicated for VTE treatment (tx) and prevention in adults
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4781950e3d9e9bf1ae6daf8f96ea40c7
https://doi.org/10.1161/circ.144.suppl_1.10571
https://doi.org/10.1161/circ.144.suppl_1.10571
Publikováno v:
American Journal of Cardiovascular Drugs
Background This was an open-label, phase I, nonrandomized, single-sequence, crossover study to evaluate the effect of concomitant administration of multiple doses of clarithromycin on the single-dose exposure, safety, and tolerability of apixaban in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ea994202bb672dbcad37eb521fcb676
http://europepmc.org/articles/PMC6885504
http://europepmc.org/articles/PMC6885504
Autor:
Jim X Shen, Yue Zhao, Jon E. Peterson, Philip Joyce, Barry R Jones, Guowen Liu, Jane Liu, David Marchisin, Suk Kwok
Publikováno v:
Bioanalysis. 10:23-33
Aim: Recombinant FGF21 analogs are under wide ranging investigations as a potential therapeutic agent for Type 2 diabetes, as well as other metabolic disorders. The endogenous FGF21 is often used as a surrogate pharmacodynamic(PD) biomarker to assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b6aadf5fe4b70b6240fdcf581370f99
https://doi.org/10.4155/bio-2017-0208
https://doi.org/10.4155/bio-2017-0208